Editing Muscle-Invasive Bladder Cancer (section)

====== Adverse events ======

* '''Cisplatin eligibility is a major determinant of candidacy for NAC'''

* '''<span style="color:#ff0000">Adverse events related to cisplatin (4):</span>'''
*# '''<span style="color:#ff0000">Nephrotoxicity</span>'''
*# '''<span style="color:#ff0000">Ototoxicity</span>'''
*# '''<span style="color:#ff0000">Neurotoxicity</span>'''
*# '''<span style="color:#ff0000">Diminished cardiac function</span>'''
** '''These preclude 30-50% of MIBC patients from safe receipt of cisplatin-based chemotherapy'''
* '''No validated predictive factors or clinical characteristics (including age) associated with an increased or decreased probability of response and benefit using cisplatin-based NAC'''
** The decision regarding eligibility for cisplatin-based NAC should be based on comorbidities and performance status, including cardiac status and presence of peripheral neuropathy, hearing loss, and renal dysfunction